Oral submucous fibrosis as an overhealing wound

Implications in malignant transformation

Mohit Sharma, Smitha S. Shetty, Raghu Radhakrishnan

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. Objective: The objective of this article is to decipher the pathogenesis of oral submucous fibrosis in order to identify novel drug targets. Methods: A thorough literature review based on oral submucous fibrosis being an overhealing wound was conducted; several related patents were identified and herewith reviewed. Necessary pathways were elaborated and deliberated in the manuscript in the form of schemas, keeping our hypothesis in mind. Several novel molecular targets were identified and discussed in detail. Results: Several patents demonstrating inhibition of fibrosis via chemokine ligand mimetics, anticon-nexon antibodies, stem cell therapy, fibronectin blocking peptides, HIF inhibitors, recombinant erythropoietin, xanthine oxidase inhibitors, long non-coding RNAs, targeting inflammation, increasing TH-1/TH-2 cytokine ratio, t-box protein 4, chromium containing compositions, Iron-based nanocomposites, Lactate Dehydrogenase-5 inhibitors, Carbonic Anhdrase-9 inhibitors, proton pump inhibitors, liposomal encapsulated glutathione, monocarboxylate-4 inhibitors, autophagy inhibitors, Submucosal anti-IL-6 antibodies, fibrin degradation products for monitoring of malignancy and fibrosis, small molecule antagonists like vorapaxar, tiplaxtinin, and TM-5275, TGF-β signalling inhibitors were identified as future therapeutic avenues. Conclusion: Considering, oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy.

Original languageEnglish
Pages (from-to)272-291
Number of pages20
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume13
Issue number3
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Oral Submucous Fibrosis
Wounds and Injuries
Patents
Fibrosis
Long Noncoding RNA
Fibrin Fibrinogen Degradation Products
Nanocomposites
Manuscripts
Antibodies
Xanthine Oxidase
Proton Pump Inhibitors
Autophagy
Chromium
Cell- and Tissue-Based Therapy
Erythropoietin
Fibronectins
Chemokines
Glutathione
Interleukin-6
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

@article{4c86c858f27641fda0f395fde55a0dca,
title = "Oral submucous fibrosis as an overhealing wound: Implications in malignant transformation",
abstract = "Background: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. Objective: The objective of this article is to decipher the pathogenesis of oral submucous fibrosis in order to identify novel drug targets. Methods: A thorough literature review based on oral submucous fibrosis being an overhealing wound was conducted; several related patents were identified and herewith reviewed. Necessary pathways were elaborated and deliberated in the manuscript in the form of schemas, keeping our hypothesis in mind. Several novel molecular targets were identified and discussed in detail. Results: Several patents demonstrating inhibition of fibrosis via chemokine ligand mimetics, anticon-nexon antibodies, stem cell therapy, fibronectin blocking peptides, HIF inhibitors, recombinant erythropoietin, xanthine oxidase inhibitors, long non-coding RNAs, targeting inflammation, increasing TH-1/TH-2 cytokine ratio, t-box protein 4, chromium containing compositions, Iron-based nanocomposites, Lactate Dehydrogenase-5 inhibitors, Carbonic Anhdrase-9 inhibitors, proton pump inhibitors, liposomal encapsulated glutathione, monocarboxylate-4 inhibitors, autophagy inhibitors, Submucosal anti-IL-6 antibodies, fibrin degradation products for monitoring of malignancy and fibrosis, small molecule antagonists like vorapaxar, tiplaxtinin, and TM-5275, TGF-β signalling inhibitors were identified as future therapeutic avenues. Conclusion: Considering, oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy.",
author = "Mohit Sharma and Shetty, {Smitha S.} and Raghu Radhakrishnan",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1574892813666180227103147",
language = "English",
volume = "13",
pages = "272--291",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

Oral submucous fibrosis as an overhealing wound : Implications in malignant transformation. / Sharma, Mohit; Shetty, Smitha S.; Radhakrishnan, Raghu.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 13, No. 3, 01.01.2018, p. 272-291.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Oral submucous fibrosis as an overhealing wound

T2 - Implications in malignant transformation

AU - Sharma, Mohit

AU - Shetty, Smitha S.

AU - Radhakrishnan, Raghu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. Objective: The objective of this article is to decipher the pathogenesis of oral submucous fibrosis in order to identify novel drug targets. Methods: A thorough literature review based on oral submucous fibrosis being an overhealing wound was conducted; several related patents were identified and herewith reviewed. Necessary pathways were elaborated and deliberated in the manuscript in the form of schemas, keeping our hypothesis in mind. Several novel molecular targets were identified and discussed in detail. Results: Several patents demonstrating inhibition of fibrosis via chemokine ligand mimetics, anticon-nexon antibodies, stem cell therapy, fibronectin blocking peptides, HIF inhibitors, recombinant erythropoietin, xanthine oxidase inhibitors, long non-coding RNAs, targeting inflammation, increasing TH-1/TH-2 cytokine ratio, t-box protein 4, chromium containing compositions, Iron-based nanocomposites, Lactate Dehydrogenase-5 inhibitors, Carbonic Anhdrase-9 inhibitors, proton pump inhibitors, liposomal encapsulated glutathione, monocarboxylate-4 inhibitors, autophagy inhibitors, Submucosal anti-IL-6 antibodies, fibrin degradation products for monitoring of malignancy and fibrosis, small molecule antagonists like vorapaxar, tiplaxtinin, and TM-5275, TGF-β signalling inhibitors were identified as future therapeutic avenues. Conclusion: Considering, oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy.

AB - Background: Oral submucous fibrosis is an oral potentially malignant disorder with high incidence of malignant transformation and rising global prevalence. However, the genesis of oral submucous fibrosis is still unclear despite superfluity of literature. In the background of ineffective treatment, it is necessary to decode its onset and progression before designing customized treatment regimens. Objective: The objective of this article is to decipher the pathogenesis of oral submucous fibrosis in order to identify novel drug targets. Methods: A thorough literature review based on oral submucous fibrosis being an overhealing wound was conducted; several related patents were identified and herewith reviewed. Necessary pathways were elaborated and deliberated in the manuscript in the form of schemas, keeping our hypothesis in mind. Several novel molecular targets were identified and discussed in detail. Results: Several patents demonstrating inhibition of fibrosis via chemokine ligand mimetics, anticon-nexon antibodies, stem cell therapy, fibronectin blocking peptides, HIF inhibitors, recombinant erythropoietin, xanthine oxidase inhibitors, long non-coding RNAs, targeting inflammation, increasing TH-1/TH-2 cytokine ratio, t-box protein 4, chromium containing compositions, Iron-based nanocomposites, Lactate Dehydrogenase-5 inhibitors, Carbonic Anhdrase-9 inhibitors, proton pump inhibitors, liposomal encapsulated glutathione, monocarboxylate-4 inhibitors, autophagy inhibitors, Submucosal anti-IL-6 antibodies, fibrin degradation products for monitoring of malignancy and fibrosis, small molecule antagonists like vorapaxar, tiplaxtinin, and TM-5275, TGF-β signalling inhibitors were identified as future therapeutic avenues. Conclusion: Considering, oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85051545228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051545228&partnerID=8YFLogxK

U2 - 10.2174/1574892813666180227103147

DO - 10.2174/1574892813666180227103147

M3 - Review article

VL - 13

SP - 272

EP - 291

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 3

ER -